Insulet Co. (NASDAQ:PODD) SVP John W. Kapples Sells 5,278 Shares

Insulet Co. (NASDAQ:PODD) SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president now owns 23,180 shares of the company’s stock, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Insulet Price Performance

PODD stock opened at $322.02 on Friday. The business has a 50 day simple moving average of $262.55 and a 200-day simple moving average of $265.81. The company has a market capitalization of $22.66 billion, a P/E ratio of 55.62, a PEG ratio of 3.62 and a beta of 1.26. Insulet Co. has a twelve month low of $170.67 and a twelve month high of $326.10. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.21. The firm had revenue of $569.00 million during the quarter, compared to analysts’ expectations of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Insulet’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.73 EPS. As a group, equities analysts anticipate that Insulet Co. will post 3.92 EPS for the current year.

Hedge Funds Weigh In On Insulet

A number of hedge funds and other institutional investors have recently made changes to their positions in PODD. Principal Financial Group Inc. lifted its stake in shares of Insulet by 4.0% in the 3rd quarter. Principal Financial Group Inc. now owns 86,210 shares of the medical instruments supplier’s stock worth $20,065,000 after acquiring an additional 3,355 shares during the period. Czech National Bank raised its stake in shares of Insulet by 6.5% during the 4th quarter. Czech National Bank now owns 15,209 shares of the medical instruments supplier’s stock worth $3,971,000 after buying an additional 926 shares in the last quarter. Cooper Financial Group raised its stake in shares of Insulet by 14.2% during the 4th quarter. Cooper Financial Group now owns 1,021 shares of the medical instruments supplier’s stock worth $267,000 after buying an additional 127 shares in the last quarter. Board of the Pension Protection Fund purchased a new stake in shares of Insulet in the fourth quarter valued at approximately $418,000. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Insulet by 8.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 104,392 shares of the medical instruments supplier’s stock valued at $27,254,000 after buying an additional 8,102 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Canaccord Genuity Group increased their price target on Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Piper Sandler upped their target price on shares of Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Royal Bank of Canada began coverage on shares of Insulet in a research note on Thursday, March 6th. They issued an “outperform” rating and a $340.00 price target for the company. StockNews.com downgraded shares of Insulet from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Finally, Wells Fargo & Company set a $322.00 price objective on shares of Insulet in a research report on Monday, April 28th. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and an average target price of $306.53.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.